Liminatus Pharma Receives Nasdaq Delisting Notice for Sub-$1 Bid Price
LIMN sits 15% above its 52-week low of $0.61 on light trading volume (0.2× avg).
Summary
Liminatus Pharma received a Nasdaq delisting notice for failing to maintain a minimum $1 bid price, initiating a 180-day compliance period to avoid potential delisting.
Key Events · Corporate Governance and Compliance · LIMN
-
Nasdaq Delisting Notice Received
On January 15, 2026, Liminatus Pharma, Inc. received a notice from Nasdaq indicating non-compliance with the minimum $1 bid price rule (Rule 5450(a)(1)) for the last 30 consecutive business days.
-
180-Day Compliance Period
The company has been granted a 180-calendar-day period, until July 14, 2026, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of ten consecutive business days.
-
Potential Reverse Stock Split
To regain compliance, the company may consider implementing a reverse stock split, which must be completed no later than ten business days prior to the compliance period's expiration.
-
No Immediate Effect on Listing
The notification does not have an immediate impact on the listing of the company's common stock, which will continue to trade on Nasdaq under the symbol 'LIMN'.
Analysis · LIMN · Life Sciences
Liminatus Pharma, a micro-cap company, has received a critical notice from Nasdaq regarding its failure to maintain the minimum $1 bid price requirement. This is a significant event as continued non-compliance could lead to the delisting of its common stock, severely impacting liquidity and investor confidence. The company has 180 days to regain compliance, which often necessitates a reverse stock split, a move that can be dilutive and negatively perceived by the market. Investors should monitor the company's actions to address this deficiency, as failure to comply poses a substantial risk to the stock's trading viability on Nasdaq.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIMN was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.61 to $33.66. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.